Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Gross Profit (2022 - 2024)

Amylyx Pharmaceuticals has reported Gross Profit over the past 3 years, most recently at -$636000.0 for Q4 2024.

  • Quarterly results put Gross Profit at -$636000.0 for Q4 2024, down 100.95% from a year ago — trailing twelve months through Sep 2025 was -$636000.0 (down 100.42% YoY), and the annual figure for FY2024 was $81.4 million, down 77.08%.
  • Gross Profit for Q4 2024 was -$636000.0 at Amylyx Pharmaceuticals, down from $416000.0 in the prior quarter.
  • Over the last five years, Gross Profit for AMLX hit a ceiling of $97.5 million in Q3 2023 and a floor of -$636000.0 in Q4 2024.
  • Median Gross Profit over the past 3 years was $44.9 million (2022), compared with a mean of $43.0 million.
  • Biggest five-year swings in Gross Profit: surged 25893.33% in 2023 and later plummeted 100.95% in 2024.
  • Amylyx Pharmaceuticals' Gross Profit stood at $23.7 million in 2022, then skyrocketed by 180.6% to $66.6 million in 2023, then plummeted by 100.95% to -$636000.0 in 2024.
  • The last three reported values for Gross Profit were -$636000.0 (Q4 2024), $416000.0 (Q3 2024), and $1.0 million (Q2 2024) per Business Quant data.